Table.1 Baseline characteristics and their association with medication overuse resolution after 6 administrations of anti-CGRP MAbs

Demographics

 Age, mean (SD), y

46.7 (9.5)

49.2 (8.2)

0.172^§

 Gender (female), n (%)

48 (80.0)

33 (84.6)

0.561^†

Baseline disease characteristics

 Duration of migraine disease, mean (SD), y

24.9 (13.9)

28.8 (11.9)

0.146^§

 Chronification time, mean (SD), y

11.8 (7.8)

13.2 (7.3)

0.359^§

 Aura, n (%)

12 (20.0)

11 (28.3)

0.345^†

 Allodynia, n (%)

29 (48.3)

20 (51.3)

0.774^†

 Unilateral pain side, n (%)

41 (68.3)

34 (87.2)

0.053^†

 Pain quality, n (%)

  Oppressive

28 (46.7)

20 (51.3)

0.653^†

  Throbbing

41 (68.3)

26 (66.7)

0.862^†

 HDM, mean (SD), d/mo

22.9 (6.0)

24.0 (5.4)

0.347^§

 MDM, mean (SD), d/mo

16.5 (6.5)

19.7 (6.4)

0.020^§

 Headache pain intensity, mean (SD), 0–3 score

1.60 (0.46)

1.85 (0.45)

0.011^§

Preventive treatment

 Anti-CGRP Treatment, n (%)

0.416^†

  Erenumab 140 mg

40 (66.7)

29 (74.4)

  Galcanezumab 120 mg (loading dose 240 mg)

24 (33.3)

9 (25.6)

Prior preventive classes failures, n (%)

0.876^†

 3 Classes

5 (8.3)

3 (7.7)

 4 Classes

24 (40.0)

15 (38.5)

 ≥ 5 Classes

31 (51.7)

21 (53.8)

Prior BTX-A efficacy^*, n (%)

0.048^†

 Partial

36/54 (66.7)

18/39 (46.2)

 Failure

18/54 (33.3)

21/39 (53.8)

 Concomitant preventive treatment, n (%)

36 (60.0)

29 (74.4)

0.142^†

 Oral concomitant medication, n (%)

31 (51.7)

26 (66.7)

0.140^†

 BTX-A concomitant medication, n (%)

20 (33.3)

18 (46.2)

0.200^†

Basal acute medication

 MO NSAIDs, n (%)

23 (38.3)

15 (38.5)

0.990^†

 MO Triptans, n (%)

46 (76.7)

33 (84.6)

0.336^†

 Acute medication frequency, mean (SD), d/mo

18.0 (6.6)

20.9 (7.4)

0.049^§

 NSAIDs frequency, mean (SD), d/mo

8.2 (7.9)

10.5 (9.5)

0.421^§

 Triptans frequency, mean (SD), d/mo

12.1 (7.3)

14.2 (8.3)

0.194^§

 BZD frequency, mean (SD), d/mo

1.2 (0.9)

5.2 (2.1)

0.034^§

 Acute medication burden, mean (SD), p/mo

24.2 (9.4)

31.2 (13.6)

0.006^§

Basal disease impact, disability and burden

 Disability (MIDAS), median [IQR]

71.5 [71.0]

95.0 [65.0]

0.117^‡

 Headache-related impact (HIT-6), mean (SD)

67.7 (12.3)

69.5 (18.8)

0.561^§

 Anxiety (BAI), median [IQR]

15.5 [19.0]

22.0 [20.0]

0.020^‡

 Depression (BDI-II), median [IQR]

11.0 [15.5]

12.0 [25.5]

0.226^‡

Treatment response rate

 HDM 50% RR, n (%)

42 (70.0)

11 (28.2)

< 0.0001‡

 MDM 50% RR, n (%)

47 (78.3)

16 (41.0)

< 0.0001^‡